SCHEMBL3969642

SCHEMBL3969642

Cc1ncccc1COc1ccc(C=O)cc1

nearest known ligand 0.57

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.57
SMN1; SMN2 Q16637 4/20 0.57
KDM4E B2RXH2 4/20 0.57
FFAR1 O14842 1/20 0.51
MEN1 O00255 1/20 0.50
KMT2A Q03164 1/20 0.50
LMNA P02545 3/20 0.49
NMT1 P30419 3/20 0.46
RAB9A P51151 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.43
MAPT P10636 1/20 0.42
HPGD P15428 1/20 0.42
OPRL1 P41146 1/20 0.41
CYP2A6 P11509 1/20 0.41
MMP1 P03956 3/20 0.40
ADAM17 P78536 2/20 0.40
MMP13 P45452 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3969638 0.80 FFAR1 (0.52) FFAR1MEN1KMT2ANMT1MMP1
SCHEMBL3962715 0.80 FFAR1 (0.51) SMN1; SMN2FFAR1MEN1KMT2ANMT1
SCHEMBL498283 0.80 MAOB (0.60) ALDH1A1SMN1; SMN2KDM4EFFAR1MEN1
SCHEMBL3962712 0.80 FFAR1 (0.51) SMN1; SMN2FFAR1MEN1KMT2ANMT1
SCHEMBL6804943 0.79 FFAR1 (0.49) FFAR1NMT1MMP1ADAM17MMP13
SCHEMBL4053035 0.76 FFAR1 (0.48) FFAR1MEN1KMT2ANMT1MMP1
SCHEMBL14675544 0.75 FFAR1 (0.60) KDM4EFFAR1MAPT
SCHEMBL14676869 0.75 FFAR1 (0.57) ALDH1A1FFAR1RAB9AMAPTHPGD
SCHEMBL2912604 0.75 ALDH1A1 (0.48) ALDH1A1SMN1; SMN2KDM4EFFAR1MEN1
Hydrochloric Acid SCHEMBL14675781 0.74 FFAR1 (0.59) KDM4EFFAR1MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9422240-B2 Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-08-23 US disclosed
US-9422240-B2 Partially saturated nitrogen-containing heterocyclic compound TAISHO PHARMACEUTICAL CO., LTD (JP) 2016-08-23 US disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND TAISHO PHARMACEUTICAL CO., LTD (JP) 2015-06-25 US disclosed
US-7595317-B2 Barbituric acid derivatives as inhibitors of TNF-α converting enzyme (TACE) and/or matrix metalloproteinases BRISTOL-MYERS SQUIBB COMPANY (US) 2009-09-29 US disclosed
US-7294624-B2 Osteoporosis; antiarthritic agents BRISTOL MYERS SQUIBB COMPANY (US) 2007-11-13 US disclosed
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES DUAN JINGWU 2007-07-19 US disclosed
WO-2003053941-A2 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-ALPHA CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES BRISTOL-MYERS SQUIBB COMPANY (US) 2003-07-03 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150175541-A1 PARTIALLY SATURATED NITROGEN-CONTAINING HETEROCYCLIC COMPOUND EGLN2, EGLN3, EGLN1 ALDH1A1 2293/4885SMN1; SMN2 2832/4885KDM4E 23/4885
US-20070167451-A1 BARBITURIC ACID DERIVATIVES AS INHIBITORS OF TNF-alpha CONVERTING ENZYME (TACE) AND/OR MATRIX METALLOPROTEINASES TNF, MMP9, MMP3 ALDH1A1 839/4885SMN1; SMN2 3011/4885KDM4E 2397/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.